Literature DB >> 35033589

ETS factors in prostate cancer.

Cheng Qian1, Dan Li2, Yu Chen3.   

Abstract

The ETS family of proteins consists of 28 transcription factors, many of which play critical roles in both normal tissue development and homeostasis and have been implicated in development and progression of a variety of cancers. In prostate cancer, gene fusion and overexpression of ETS factors ERG, FLI1, ETV1, ETV4 and ETV5 have been found in half of prostate cancer patients in Caucasian men and define the largest genetic subtype of prostate cancer. This review summarizes the data on the discovery, modeling, molecular taxonomy, lineage plasticity and therapeutic targeting of ETS family members in prostate cancer.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Androgen receptor; ERG; Oncogenic translocations; Prostate cancer; Transcription factors

Mesh：

Substances：

Year:  2022        PMID： 35033589      PMCID： PMC8832285          DOI： 10.1016/j.canlet.2022.01.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  130 in total

1.  ERF nuclear shuttling, a continuous monitor of Erk activity that links it to cell cycle progression.

Authors:  Lionel Le Gallic; Laura Virgilio; Philip Cohen; Benoit Biteau; George Mavrothalassitis
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

2.  Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation.

Authors:  Nahyun Choi; Boyu Zhang; Li Zhang; Michael Ittmann; Li Xin
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

3.  The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain.

Authors:  R Marais; J Wynne; R Treisman
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

4.  TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.

Authors:  Outi R Saramäki; Anna E Harjula; Paula M Martikainen; Robert L Vessella; Teuvo L J Tammela; Tapio Visakorpi
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

5.  TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.

Authors:  Orla M Casey; Lei Fang; Paul G Hynes; Wassim G Abou-Kheir; Philip L Martin; Heather S Tillman; Gyorgy Petrovics; Hibah O Awwad; Yvona Ward; Ross Lake; Luhua Zhang; Kathleen Kelly
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

6.  Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

Authors:  Maha Hussain; Stephanie Daignault-Newton; Przemyslaw W Twardowski; Costantine Albany; Mark N Stein; Lakshmi P Kunju; Javed Siddiqui; Yi-Mi Wu; Dan Robinson; Robert J Lonigro; Xuhong Cao; Scott A Tomlins; Rohit Mehra; Kathleen A Cooney; Bruce Montgomery; Emmanuel S Antonarakis; Daniel H Shevrin; Paul G Corn; Young E Whang; David C Smith; Megan V Caram; Karen E Knudsen; Walter M Stadler; Felix Y Feng; Arul M Chinnaiyan
Journal:  J Clin Oncol       Date:  2017-12-20       Impact factor: 44.544

7.  Organoid cultures derived from patients with advanced prostate cancer.

Authors:  Dong Gao; Ian Vela; Andrea Sboner; Phillip J Iaquinta; Wouter R Karthaus; Anuradha Gopalan; Catherine Dowling; Jackline N Wanjala; Eva A Undvall; Vivek K Arora; John Wongvipat; Myriam Kossai; Sinan Ramazanoglu; Luendreo P Barboza; Wei Di; Zhen Cao; Qi Fan Zhang; Inna Sirota; Leili Ran; Theresa Y MacDonald; Himisha Beltran; Juan-Miguel Mosquera; Karim A Touijer; Peter T Scardino; Vincent P Laudone; Kristen R Curtis; Dana E Rathkopf; Michael J Morris; Daniel C Danila; Susan F Slovin; Stephen B Solomon; James A Eastham; Ping Chi; Brett Carver; Mark A Rubin; Howard I Scher; Hans Clevers; Charles L Sawyers; Yu Chen
Journal:  Cell       Date:  2014-09-04       Impact factor: 41.582

8.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

9.  Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.

Authors:  Toni K Choueiri; Todd M Bauer; Kyriakos P Papadopoulos; Elizabeth R Plimack; Jaime R Merchan; David F McDermott; M Dror Michaelson; Leonard J Appleman; Sanjay Thamake; Rodolfo F Perini; Naseem J Zojwalla; Eric Jonasch
Journal:  Nat Med       Date:  2021-04-22       Impact factor: 87.241

10.  ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.

Authors:  Zineb Mounir; Joshua M Korn; Thomas Westerling; Fallon Lin; Christina A Kirby; Markus Schirle; Gregg McAllister; Greg Hoffman; Nadire Ramadan; Anke Hartung; Yan Feng; David Randal Kipp; Christopher Quinn; Michelle Fodor; Jason Baird; Marie Schoumacher; Ronald Meyer; James Deeds; Gilles Buchwalter; Travis Stams; Nicholas Keen; William R Sellers; Myles Brown; Raymond A Pagliarini
Journal:  Elife       Date:  2016-05-16       Impact factor: 8.140
View more
  1 in total

1.  Oncogenic ACSM1 in prostate cancer is through metabolic and extracellular matrix-receptor interaction signaling pathways.

Authors:  Yongchen Guo; Chunna Ren; Wentao Huang; Wancai Yang; Yonghua Bao
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.